Conclusions and implications
The nanoreactors containing GOx activity are fully suitable for cytotoxicity generation in tumor cells. The HSA functionalization of the VLP-GOx nanoreactors could result in a prevailing strategy to improve selective cancer targeting. The GOx containing enzymatic nanoreactors seems to be an interesting alternative to improve the current cancer therapy. In vivo studies are ongoing to reinforce the effectiveness of this treatment strategy.